Despite considerable advances in the treatment of multiple myeloma (MM) in the last
decade, a substantial proportion of patients do not respond to current therapies or have a …

Genetically engineered T cells are powerful new medicines, offering hope for curative
responses in patients with cancer. Chimeric antigen receptor (CAR) T cells were recently …

Abstract Background LCAR-B38M is a chimeric antigen receptor T cell product with two
binding domains targeting B cell maturation antigen. Our previous reports showed a …

Immune-based therapies hold promise for the treatment of multiple myeloma (MM), but so
far, immune checkpoint blockade targeting programmed cell death protein 1 has not proven …

Despite a substantial survival improvement and the availability of many new drugs in the last
2 decades, multiple myeloma (MM) remains largely incurable. Immunotherapeutic …

Patients with multiple myeloma have a compromised immune system, due to both the
disease and antimyeloma therapies, and may therefore be particularly susceptible to COVID …

The clinical signs of multiple myeloma, a plasma cell (PC) dyscrasia, include bone loss,
renal damage, and paraproteinemia. It can be defined as the uncontrolled growth of …

Introduction: Multiple myeloma (MM) is a currently incurable hematologic tumor with
heterogeneous clinical behavior and prognosis. During the last years, survival improved due …

Multiple myeloma (MM) is a hematological cancer caused by abnormal proliferation of
plasma cells in the bone marrow, and novel types of treatment are needed for this deadly …

The cell-surface protein B cell maturation antigen (BCMA, CD269) has emerged as a
promising target for CAR-T cell therapy for multiple myeloma. In order to create a novel …